Corium Prices Offering of $100 Million of 5% Convertible Senior Notes
MENLO PARK, Calif. , March 01, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the pricing of its offering of $100,000,000…
Corium Announces Proposed Offering of $100 Million of Convertible Senior Notes; Receives FDA Feedback on Pilot Bioequivalence Study
MENLO PARK, Calif. , Feb. 28, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that it intends to offer, subject to market…
Corium Reports First Quarter Fiscal 2018 Finaical Results and Corporate Highlights
MENLO PARK, Calif. , Feb. 08, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the first…
Corium to Present at Upcoming Healthcare Investor Conferences
MENLO PARK, Calif. , Feb. 06, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that the company will be participating in…
Corium to report First Quarter Fiscal 2018 Financial Results on Thursday, February 8, 2018
MENLO PARK, Calif. , Feb. 01, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the first quarter ended December 31, 2017 on February 8, 2018 after the close of the U.S. financial markets. Corium will host a conference call…
